Cessation Therapeutics

Cessation Therapeutics is a clinical-stage biotechnology company dedicated to developing biologics for substance abuse. Cessation's monoclonal antibodies are initially focused primarily on fentanyl but can also target future synthetic opioids and other substances. Cessation’s investigational products hold promise for treating a range of substance use disorders and improving the lives of patients and families affected by the addiction crisis.